PCRX
Income statement / Annual
Last year (2025), Pacira BioSciences Inc's total revenue was $726.41 M,
an increase of 3.63% from the previous year.
In 2025, Pacira BioSciences Inc's net income was $7.03 M.
See Pacira BioSciences Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$726.41 M |
$700.97 M |
$674.98 M |
$666.82 M |
$541.53 M |
$429.65 M |
$421.03 M |
$337.28 M |
$286.63 M |
$276.37 M |
| Cost of Revenue |
$149.75 M
|
$170.43 M
|
$184.67 M
|
$199.30 M
|
$140.26 M
|
$117.33 M
|
$106.71 M
|
$86.85 M
|
$87.92 M
|
$110.10 M
|
| Gross Profit |
$576.66 M
|
$530.54 M
|
$490.31 M
|
$467.53 M
|
$401.28 M
|
$312.32 M
|
$314.31 M
|
$250.43 M
|
$198.72 M
|
$166.27 M
|
| Gross Profit Ratio |
0.79
|
0.76
|
0.73
|
0.7
|
0.74
|
0.73
|
0.75
|
0.74
|
0.69
|
0.6
|
| Research and Development Expenses |
$117.31 M
|
$81.58 M
|
$76.26 M
|
$84.80 M
|
$55.55 M
|
$59.42 M
|
$72.12 M
|
$55.69 M
|
$57.29 M
|
$45.68 M
|
| General & Administrative Expenses |
$142.14 M
|
$122.08 M
|
$116.40 M
|
$109.52 M
|
$88.32 M
|
$74.83 M
|
$71.12 M
|
$70.16 M
|
$66.69 M
|
$63.40 M
|
| Selling & Marketing Expenses |
$226.62 M
|
$172.02 M
|
$153.04 M
|
$145.00 M
|
$111.02 M
|
$118.68 M
|
$129.66 M
|
$107.11 M
|
$94.80 M
|
$89.22 M
|
| Selling, General & Administrative Expenses |
$368.76 M
|
$294.10 M
|
$269.44 M
|
$254.52 M
|
$199.35 M
|
$193.52 M
|
$200.78 M
|
$177.27 M
|
$161.49 M
|
$152.61 M
|
| Other Expenses |
$57.29 M
|
$228.23 M
|
$56.94 M
|
$68.19 M
|
$56.46 M
|
$13.03 M
|
$30.93 M
|
-$888.00 K
|
$167.00 K
|
-$82.00 K
|
| Operating Expenses |
$543.36 M
|
$603.91 M
|
$402.63 M
|
$407.50 M
|
$311.35 M
|
$265.97 M
|
$303.83 M
|
$232.95 M
|
$218.78 M
|
$198.29 M
|
| Cost And Expenses |
$693.11 M
|
$774.34 M
|
$587.30 M
|
$606.80 M
|
$451.61 M
|
$383.30 M
|
$410.55 M
|
$319.80 M
|
$306.70 M
|
$308.40 M
|
| Interest Income |
$22.73 M
|
$19.69 M
|
$11.44 M
|
$4.54 M
|
$896.00 K
|
$4.63 M
|
$7.38 M
|
$6.50 M
|
$4.08 M
|
$1.32 M
|
| Interest Expense |
$14.61 M
|
$16.57 M
|
$17.31 M
|
$35.58 M
|
$29.00 M
|
$25.67 M
|
$23.63 M
|
$21.95 M
|
$18.05 M
|
$7.06 M
|
| Depreciation & Amortization |
$91.02 M
|
$78.79 M
|
$75.57 M
|
$91.50 M
|
$28.55 M
|
$19.91 M
|
$19.58 M
|
$13.17 M
|
$13.83 M
|
$12.92 M
|
| EBITDA |
$122.50 M |
$29.12 M |
$154.59 M |
$140.38 M |
$113.95 M |
$63.51 M |
$30.75 M |
$33.06 M |
-$10.59 M |
-$17.86 M |
| EBITDA Ratio |
0.17
|
0.04
|
0.23
|
0.21
|
0.21
|
0.15
|
0.07
|
0.1
|
-0.04
|
-0.06
|
| Operating Income Ratio |
0.05
|
-0.1
|
0.13
|
0.09
|
0.17
|
0.11
|
0.02
|
0.05
|
-0.09
|
-0.12
|
| Total Other Income/Expenses Net |
-$16.43 M
|
$10.27 M
|
-$25.97 M
|
-$46.72 M
|
-$33.52 M
|
-$26.26 M
|
-$21.23 M
|
-$16.34 M
|
-$17.53 M
|
-$5.82 M
|
| Income Before Tax |
$16.87 M
|
-$63.11 M
|
$61.70 M
|
$13.30 M
|
$56.40 M
|
$20.09 M
|
-$10.75 M
|
-$425.00 K
|
-$42.47 M
|
-$37.84 M
|
| Income Before Tax Ratio |
0.02
|
-0.09
|
0.09
|
0.02
|
0.1
|
0.05
|
-0.03
|
-0
|
-0.15
|
-0.14
|
| Income Tax Expense |
$9.84 M
|
$36.45 M
|
$19.75 M
|
-$2.61 M
|
$14.42 M
|
-$125.43 M
|
$268.00 K
|
$46.00 K
|
$140.00 K
|
$105.00 K
|
| Net Income |
$7.03 M
|
-$99.56 M
|
$41.96 M
|
$15.91 M
|
$41.98 M
|
$145.52 M
|
-$11.02 M
|
-$471.00 K
|
-$42.61 M
|
-$37.95 M
|
| Net Income Ratio |
0.01
|
-0.14
|
0.06
|
0.02
|
0.08
|
0.34
|
-0.03
|
-0
|
-0.15
|
-0.14
|
| EPS |
0.16 |
-2.15 |
0.91 |
0.35 |
0.95 |
3.41 |
-0.27 |
-0.0115 |
-1.07 |
-1.02 |
| EPS Diluted |
0.16 |
-2.15 |
0.89 |
0.34 |
0.92 |
3.33 |
-0.27 |
-0.0115 |
-1.07 |
-1.02 |
| Weighted Average Shares Out |
$44.57 M
|
$46.25 M
|
$46.22 M
|
$45.52 M
|
$44.26 M
|
$42.67 M
|
$41.51 M
|
$40.91 M
|
$39.81 M
|
$37.20 M
|
| Weighted Average Shares Out Diluted |
$45.04 M
|
$46.25 M
|
$51.98 M
|
$46.54 M
|
$45.63 M
|
$43.68 M
|
$41.51 M
|
$40.91 M
|
$39.81 M
|
$37.24 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
